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Abstract 
Autoimmune Addison’s disease (AAD) is caused by an immunological destruction of 
the steroid producing cells of the adrenal cortex. Both genetic and environmental 
factors are involved in disease development, and while multiple studies have 
highlighted several genes linked to the disease, far less is known about possible 
environmental factors and the role played by the adrenal tissue itself.  
By studying the well-established human adrenocortical carcinoma cell line NCI-
H295R as a model of the adrenal cortex, adrenal cells were shown to respond to 
environmental factors in the form of virus induced type I and III interferons (IFNs) by 
potentiating chemokine production and by upregulation of MHC class I and the tissue 
specific enzyme 21-hydroxylase (21OH). This can be important traits in the T cell-
mediated adrenal tissue destruction, recruiting potentially 21OH-specific autoreactive 
T cells to the tissue. In addition, the same IFNs were shown to have a direct cytotoxic 
effect on the adrenocortical cells.  
From a large clinical material we have found that AAD patients have elevated levels 
of the chemokines CXCL10 and CXCL9 in their sera, while producing significantly 
lower levels of the same chemokines after stimulation of PBMC with type I and II 
IFNs and the TLR3 ligand poly (I:C). This is also the case when investigating the 
relative mRNA expression of selected IFN stimulated genes (ISGs) after IFN or poly 
(I:C) stimulation.  
Cytomegalovirus (CMV) has been implicated in autoimmune disease development, 
including AAD. Nevertheless, we found that AAD patients in general have normal 
humoral and cellular immunity towards CMV, with no differences in CD8+ T cell 
specific responses. However, the AAD patients were found to have significantly 
lower levels of total circulating CD8+ T cells. While CMV infections do not appear to 
be linked to AAD disease development in general, individual patients showed signs 
supporting CMV as a possible perpetrator. One patient had serological signs 
suggesting a reactivating CMV infection, while having extremely low levels of CMV 
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specific CD8+ T cells. The same patient was also part of the chemokine study, where 
she had low chemokine production after IFN stimuli in addition to an upregulation of 
three ISGs in her peripheral blood. Intriguingly, the daughter of this patient also had 
AAD and, despite of being anti-CMV IgG positive, had virtually no CMV specific 
CD8+ T cells. These findings suggest that an inheritable immunological phenotype 
may increase individuals’ susceptibility to develop AAD, but also impair their ability 
to control viral infections.  
Taken together, the work included in this thesis provides important insight into AAD 
development. We have shown using adrenocortical cells that the adrenal cortex could 
play a part in its own destruction in response to interferons induced by viruses. 
Furthermore, while having a normal cellular and humoral immunity towards the 
common virus CMV, the innate immune system of AAD patients does not appear to 
function optimally. Thus for individual patients, CMV infection could be a 
precipitating event in disease development. 
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1. Introduction 
Autoimmune Addison’s disease, or primary adrenocortical insufficiency, is a 
prototypic autoimmune endocrine disorder characterized by the destruction of the 
cells in the adrenal cortex. Understanding the term autoimmunity comes from 
knowledge of the term immunity. Immunity is the ability to resist and fight attacks 
from possible intruders. The host, or in this case, the human body, is equipped with 
an immune system consisting of several specific immune cells and molecular 
components that help the body escape and eradicate infections. These infections 
could be a result of microbes entering through the skin, airways or gastrointestinal 
tract.  
We are dependent on our immune system for survival, but the mechanisms of the 
immune system could potentially also cause significant morbidity or even death. One 
way this might happen is when the cells of the immune system lose their ability to 
discriminate foreign (non-self) antigens from self-antigens. This response to self is a 
phenomenon known as autoimmunity, which in turn could lead to cells of the 
immune system attacking and destroying normal tissues within the body, an 
autoimmune disease.  
First this thesis gives a brief introduction of the immune system and its components, 
followed by antiviral immunity and autoimmune diseases. The main focus will then 
be on Addison’s disease and how viral infections and antiviral immunity could be 
important mediators in the development of autoimmune Addison’s disease. 
 
1.1 Innate immunity 
The immune system is divided into two different compartments with highly 
specialized immune cells. The innate immune response is the host’s first line defense 
and is essential for an early response against intruding pathogens. This early immune 
response is orchestrated by immune cells such as macrophages, neutrophils, mast 
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cells, dendritic cells (DCs) and natural killer (NK) cells [1]. These cells ingest 
(phagocytose) and destroy microbes, activate the complement system and produce 
cytokines and chemokines, signal molecules that activate and recruit additional cells 
to the affected area [1]. The complement system is a set of plasma proteins that 
ultimately may lead to lysis of bacteria and infected cells [2]. 
The components of the innate immune system are ancient, and have evolved to 
recognize highly conserved pathogen associated molecular patterns (PAMP) on the 
intruders by the use of pattern recognition receptors (PRR) [3]. The best described 
PRR are the Toll like receptors (TLRs) recognizing bacterial cell wall components 
and nucleic acids of virus and bacteria. They were first discovered in Drosophila 
melanogaster, and a few years later they were also identified in humans [4, 5]. TLRs 
are located in different compartments of the cell, such as within the cytosol, on the 
cell surface, or inside endosomes which are exposed to different kinds of microbes 
[5]. The innate immune system is also responsible for the activation and initial 
stimulation of the adaptive immune response, as described below. 
 
1.2 Adaptive immunity 
Adaptive immunity is the ability to recognize and respond specifically to a first time 
infection, and to learn and adapt with a quicker response the next time around. 
Adaptive immunity is dependent on antigen recognition, leading to lymphocyte 
activation and migration to infected tissue. The antigen recognition is highly specific, 
and only a few initial clones of lymphocytes will share receptors specific for the same 
antigen. The lymphocytes of the adaptive immune system are the T (Thymus derived) 
lymphocytes which carry the T cell receptor (TcR) and the B (Bone-marrow derived) 
lymphocytes carrying the B cell receptor (BcR). These two types of lymphocytes 
have very different actions of antigen binding and cellular activation, but similar for 
both is the vast array of possible receptors displayed on the cells surfaces. The 
antigen-binding site is made up by variable regions, encoded by three classes of 
different gene segments which is brought together by a unique recombinatory process 
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that theoretically could give rise to about 1015 different antigen specificities for B- 
and T cells [6].   
1.2.1 Antigen presentation, TcR binding and activation 
The secondary lymphoid organs, such as the spleen and lymph nodes play a very 
important role in the immune system. Here the T cells encounter professional antigen 
presenting cells (APC), for instance DCs and macrophages, bringing antigens to these 
lymphoid organs from different sites of the body. These antigens are portrayed as 
peptides bound to major histocompatibility complex (MHC) molecules, also known 
as human leucocyte antigen (HLA) in humans. The antigen is processed from 
intracellular or extracellular microbes and presented by MHC class I or MHC class II 
respectively. MHC Class II is expressed primarily by the professional APCs 
macrophages, DCs, B Cells, monocytes and endothelial cells while MHC class I is 
expressed, at varying degrees, on most cells of the body [7]. Antigens encountered 
extracellularly are ingested through the acidic environment in vesicles in the cell, 
these vesicles then fuse with others carrying the MHC class II molecules, which bind 
antigen peptides varying from 13-17 amino acids in length and present them on the 
cell surface to T cells [7, 8]. When a cell is infected by a microbe the antigen may be 
found in the cytosol, where it is degraded and transferred to the endoplasmic 
reticulum (ER). In the ER, peptides consisting of 8-10 amino acids encounters the 
MHC class I and the receptor-peptide complex is transferred to the cell surface to be 
presented for T cells [9].  
In addition to being responsible for transferring antigens to sites of recognition and 
presenting these antigens in a manner enabling identification by specific 
lymphocytes, APC also needs to provide additional “signals” to activate T cells. This 
is part of a three-step process of T cell activation that also underlines the importance 
of the innate immune system in the activation of adaptive immunity. The first step is 
the actual binding of the TcR to the MHC complex bearing the peptide. In addition, 
there is also co-stimulatory binding of a second receptor on the T cell, the Cluster of 
Differentiation (CD) 28 receptor bound to the B7 ligand (CD80/CD86) on the APC 
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[10]. Binding of microbial PAMPs to PRR enhances expression of B7 on the APC 
and leads to secretion of inflammatory signal molecules such as cytokines and 
chemokines [11]. These secreted molecules contribute the third signal in the 
activation process of naïve T cells.   
 
Figure 1: Co-stimulation in T cell activation. T cells are dependent on expression and secretion of 
co-stimulators for activation. If the APC does not express the B7 ligand or secrete stimulatory 
cytokines the T cell will not respond to MHC binding, but rather enter a state of unresponsiveness (a 
mechanism termed anergy). When APCs are activated as part of an innate immune response to 
microbes, co-stimulators will be expressed and the T cells activated. This ensures that T cells will not 
respond to antigens that inflict no danger to the body. 
The same co-stimulatory process explained in Figure 1, is also used by the immune 
system in an inhibitory fashion. While CD28-B7 binding is important in initial T cell 
activation, activated T cells also start to express a down-regulatory receptor, 
cytotoxic T-lymphocyte-associated protein 4 (CTLA4), that binds to B7 on APCs and 
inhibits the T cell response by diminishing T cell proliferation and production of 
cytokines [12]. 
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1.2.2 T cell subsets and phenotypes 
The T cells are divided into two main subsets based on whether they carry the co-
receptor CD4 or CD8, and are then further classified into subtypes. Co-receptor CD4 
is responsible for MHC class II binding, while CD8 recognize MHC class I. Once an 
antigen is encountered by the antigen-specific naïve T cell (as described above), a 
process of activation and proliferation of that T lymphocyte is initiated. The CD4+ T 
cells differentiate into different effector (helper) and regulatory T (Tregs) cell subsets.  
The cytokines produced by the APC during antigen recognition drives the activation 
of transcription factors and the differentiation of the T cell into the main effector 
subtypes (Th1, Th2 and Th17) [13]; the differentiation into Th1 cells are driven by a 
combination of IFN-γ and IL-12, and they are important effector cells in the immune 
response against intracellular pathogens. Another subtype is the Th2 cells, their 
differentiation is mediated by IL-4 and IL-2, and these cells are important in the 
defense against extracellular parasites. Th2 cells are often associated with allergy and 
asthma [14]. The differentiation into a third subtype of helper cells, the Th17, is 
driven by TGFβ-1, IL-6, IL-21 and IL-23. These cells mediate the immune response 
against extracellular bacteria and fungi [15]. The CD4+ T helper (Th) cells are 
responsible for activation of macrophages, CD8+ T cells and B cells and produce a 
range of cytokines that differentiate and fine-tunes the immune response [11], as 
shown in Figure 2. Follicular helper T cells (Tfh) enter the follicles of lymphoid 
organs and are the most powerful activator of B cells which stimulates the production 
of antibodies [16].  
 19 
 
Figure 2: Development of different CD4+ helper T cells. The naïve CD4+ T cell give rise to several 
T helper cell subtypes specific for different infectious pathways. These subsets produce a variation of 
cytokines essential for activation of the different immune cells. The different subsets could also 
present as possible perpetrators in various diseases.   
While the different Th cell subsets are responsible for actions that are pro-
inflammatory, the Tregs are important contributors in dampening of inflammation 
and for inhibiting the effector cascade. These cells are either thymus-derived Tregs 
(tTregs) (also known as natural (nTregs)) that are presented to different self-antigens 
in the thymus, or peripherally derived Tregs (pTregs) generated in the periphery 
when naïve T cells are introduced to persistent self-antigens and IL-2 during T cell 
maturation  [17-19].  
Activation of naïve CD8+ T cells leads to differentiation into cytotoxic T 
lymphocytes (CTLs), which are responsible for killing infected cells, typically virus 
infected cells that present the antigen bound to MHC class I molecules [10]. These 
cells will be described further below in relation to antiviral immunity. 
1.2.3 B cells and antibodies 
While T cells only recognize the peptides presented in the context of MHC on other 
cells, B cells recognize native antigens. The B cells are responsible for the humoral 
adaptive immune response of the host. This response is initiated when antigen 
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interacts with the BcR on the B cell membrane and, given that the B cell receives the 
appropriate help from Th cells, antibodies of the same antigen specificity are secreted 
as a soluble form of the BcR from the cell. The B cell antibodies are 
immunoglobulins of five different isotypes, IgA, IgD, IgE, IgG and IgM [6]. The 
antibodies have several effector functions, including neutralization of toxins, marking 
microbes for destruction, activation of complement and inflammation among others 
[20]. The activated B cell undergoes clonal expansion and differentiates into short 
and long-lived plasma cells and memory B cells [6].  
1.2.4 Immunological tolerance 
Immunological tolerance is the ability of a lymphocyte not to respond to certain 
antigens. This is the immune systems way of ensuring that the lymphoid cells do not 
react towards self-tissue or cells by a complex process that eliminate lymphocytes 
responding to self [11]. Immunological tolerance is divided into central and 
peripheral, where the central tolerance takes place in the generative (primary) 
lymphoid organs, and peripheral tolerance in peripheral tissues and compartments.  
The central tolerance of T cells consists of a positive and a negative selection which 
takes place in the thymus, where the immature T cells migrate from the bone marrow. 
The positive selection takes place in the outer thymic cortex, where double positive 
CD4+CD8+ cells are generated and interacts with MHC class I/II presented by cortical 
thymic epithelial cells through their TcR. The cells with no affinity to the MHC will 
undergo apoptosis or death by neglect, while cells able to interact will continue the 
migration to the medulla as either CD4+ or CD8+ T cells [21]. In the medulla the T 
cells and their receptors are presented to MHC class I/II presenting self-antigens on 
intrathymic APCs, such as DCs, medullary thymic epithelial cells (mTECs) and B 
cells [22]. If the TcR have low affinity to the presented MHC/peptide complex, it is 
assumed that they will not respond to self and therefore the naïve T cell are allowed 
to migrate further to peripheral tissues. However, T cells carrying receptors with high 
affinity for the self-peptides will be marked for destruction (apoptosis) in the negative 
selection process [23]. Another fate for the immature T cells binding to self-antigens 
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is development into Tregs [24]. Although central tolerance exists to avoid self-
reactive cells to enter the periphery, this is not always the case. All self-reactive T 
cells that bind with low and intermediate affinity to the self-peptides cannot be 
eliminated, in part since not all self-antigens are expressed in the thymus [25]. 
Peripheral tolerance is another layer of regulation to restrain self-reactive T cells in 
the periphery with three different outcomes. (I) The T cell could become anergic, 
functionally inactivated, when recognizing the peptide without proper co-stimulation, 
(II) the APCs or DCs in particular could send signals of deletion (apoptosis) or (III) 
there could be a suppression of the T cells in cooperation with Tregs [25, 26]. 
Central tolerance development for B cells takes place in the bone marrow. A BcR that 
binds self-antigen with high affinity will undergo receptor editing, exchanging the 
autoreactive part of the immunoglobulin receptor through the process of gene 
rearrangement [27]. If the receptor editing is unsuccessful, the B cell will die by 
apoptosis [28]. In the periphery, the fate of the B cells recognizing self-antigens 
without proper T cell co-stimulation is anergy [29]. In the spleen and lymph nodes 
helper T cells can contribute to deletion of autoreactive B cells by apoptosis in a Fas 
(CD95) dependent matter [30, 31].  
 
1.3 Antiviral immunity 
When a virus invades the host it has a relatively short lifespan outside the cells. 
However, if the virus manages to infect the cells of the host, it replicates within the 
cell and the infection can then spread throughout the body. Detection of the infection 
first triggers an innate immune response, followed by a cascade of actions that 
activate adaptive immunity, CTL in particular, as a result of antigen presentation and 
cytokine secretion [32]. Antibodies are also important in detecting and neutralizing 
viruses outside the cells [33].  Interferons (IFNs) are a class of cytokines important 
both in the innate and adaptive immune responses having antiviral, antiproliferative 
and immumodulatory effects. They consist of three families: The type I interferons, 
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the type II interferon or IFN-γ, and the type III interferons [34]. NK cells and T cells 
are the predominant producers of IFN-γ, acting on several cell types, macrophages 
and monocytes in particular, carrying the IFN-γ receptor [35]. Virus infected cells 
secrete type I interferons and other cytokines such as IL-12 that bind directly to their 
receptors on NK cells and T cells and function as costimulatory molecules activating 
signaling pathways leading to production of IFN-γ [36-38]. The most recent 
discovered IFN family are the type III interferons, including IFNλ1, IFNλ2, IFNλ3 
and IFNλ4 [39-41]. The type III interferons have similar properties as the type I 
interferons and they are produced by most cell types, DCs in particular, but they have 
a more restricted potential since their receptor is mainly expressed on epithelial cells 
[42].   
1.3.1 Type I Interferons 
Type I IFNs were the first cytokines discovered and today several different variants 
are known [43]. IFN-α (13 subtypes), IFN-β, IFN-ε, IFN-κ and IFN-ω are all 
different variants of type I IFNs identified in humans [44]. IFN-α and –β are the most 
common and best studied subtypes, and are essential to the immune system in 
clearing viral infections. When pathogens enter the body and stimulate PRR, most 
cells are capable of producing IFN-α and –β as a response, but the major producers 
are the plasmacytoid dendritic cells (pDC) [45]. In viral infections the TLRs of the 
endosomes, such as TLR3, 7, 8 and 9 expressed in different subsets of IFN-producing 
cells, play an important role in binding to double-stranded RNA, single-stranded 
RNA and microbial DNA [46]. Type I IFNs also play an important part in the 
activation of the adaptive immune response through innate immunity, by inducing the 
expression of the co-stimulatory molecules and MHC class I on the APCs needed to 
activate CD8+ T cells [47].     
During a viral infection the type I interferons interfere with the viral replication by 
induction of interferon stimulated genes (ISGs). This induction is the result of a 
signaling cascade starting with IFN-α/β binding to their common receptor, a complex 
of IFNAR1 and IFNAR2 subunits expressed on a wide variety of cell types, leading 
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to the stimulation of the JAK-STAT pathway following induction and expression of 
hundreds of ISGs [34, 48, 49]. These genes are involved in several steps of the 
process of inhibiting and clearing the infection, from enhancing production of pro-
inflammatory cytokines to dampening the response by anti-inflammatory cytokines 
and mediators. The chemokine CXC chemokine ligand 10 (CXCL10) is a classic 
example of an ISG, which is upregulated both in response to IFN-α/β and IFN-γ [50, 
51]. The CXCL10 binds to its chemokine ligand CXCR3 on lymphocytes in order to 
recruit them to the sites of infection [52]. 
 
Figure 3: Diverse roles for interferon stimulated genes (ISGs) in the IFN antiviral pathway.  
During a viral infection the pathogen associated molecular patters on the virus is sensed by the 
pattern recognition receptors (PRR). This in turn leads to activation of interferon regulatory factors 
(IRFs) and transcriptional induction of IFNs. The IFNs signal through the Janus kinase and Signal 
transducer and activator of transcription (JAK/STAT) pathway and induces production of ISGs. This 
main process is illustrated with the large white arrows. The IRFs can also induce some ISGs directly 
without induction of IFNs (thin blue arrow). Some ISGs block viral replication (blocked red line). 
The red arrows are the ISG that is part of the IFN signaling pathway or leads to production of more 
IFNs. The negative regulators of the cascade are illustrated by the dotted lines, targeting the cascade 
at various time points.  Adapted from Schoggins and Rice, 2011, produced using Servier Medical Art 
(http://www.servier.com/Powerpoint-image-bank) 
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1.3.2 Cytotoxic T cells 
Once naïve CD8+ T cells are activated in the lymph node or spleen, they can 
differentiate into effector CD8+ T cells, or cytotoxic T lymphocytes (CTLs). Type I 
and II IFNs are important mediators in the CD8+ T cell response by functioning as co-
stimulators that augments CD8+ T cell activation and proliferation, by inducing ISGs 
affecting the T cells and also by increasing expression of MHC class I on APCs (DCs 
especially) [48, 53]. As mentioned earlier, the MHC class I molecules are expressed 
on almost all nucleated cells of the body, making the CTL able to respond against 
intracellular pathogens in most tissues and thereby assist in viral clearance. The 
activated T cells upregulate the expression of the inflammatory chemokine receptors 
such as CXCR3 which allow them to bind to IFN induced chemokines released by 
APCs in response to viral infections (ISGs) and guide them from the site of 
recognition to the site of infection in the peripheral tissues [54]. 
CTL are very efficient in clearing of infections. By inducing apoptosis of the infected 
cells they destroy the components the virus needs to replicate and survive [32]. The 
main effector mechanism of CTLs is calcium dependent release of cytotoxic granules 
containing proteins specific for CTLs, such as perforin and granzymes [55, 56]. The 
perforin assists in the entering of granzymes through the membrane of the infected 
cell, where the granzymes induce apoptosis through various actions [56, 57]. CTL 
may also kill target cells by upregulation of the Fas ligand (CD95L) and interacting 
with Fas (CD95) on the target cell. The target can also be other lymphocytes in the 
process of terminating the lymphocyte proliferation after viral infection is cleared 
[58]. The activated CTL produces high amounts of IFN-γ, sustaining the inflamed 
environment by further stimulation of cells located in the inflamed tissue [35].  
 
1.4 Autoimmunity and autoimmune diseases 
During their normal development, the cells of the adaptive immune system, or rather 
their receptors are introduced to antigens that are part of the body to evade 
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immunological actions to self. Autoimmunity as by definition is failure of 
immunological tolerance. In this situation adaptive immune cells mistake self-
antigens for foreign and destroys the cells that express them or produce antibodies 
against self (autoantibodies). Some degree of autoimmunity is probably beneficial for 
the organism, for instance in the context of the central nervous system where self-
specific T cells has been shown to aid in tissue repair [59]. But when a large scale 
immunological response leading to destruction of vital organs and tissues is activated, 
it turns into an autoimmune disease. Autoimmune diseases have a huge impact on 
society in the western world, affecting 5-10% of the population, ranking as the third 
most prevalent cause of disease and the tenth leading cause of death in American 
females [60-62]. Autoimmune diseases are either systemic, targeting several organs 
or tissues, or organ specific, where especially the endocrine organs seems to be at risk 
[63].  
Today’s knowledge of what actually cause autoimmune disease is limited, but three 
different components are believed to contribute: A genetic predisposition, 
environmental factors and failure of immune regulation. There are rare examples 
where mutations in a single gene cause autoimmune disease, for instance in the 
autoimmune regulator (AIRE) gene which leads to autoimmune polyendocrine 
syndrome type I (APS-1) [64], but in most autoimmune diseases several different 
genes and gene combinations are believed to contribute. The genes encoding antigen 
presenting molecules, HLA (MHC) class I and class II, have a strong link to many 
autoimmune diseases. These genes are highly polymorphic, giving rise to a great 
variation in the shape, size and charge of the peptide binding pocket of the protein 
they encode. One amino acid change could regulate the degree of interaction between 
the HLA peptide binding grove and the antigen or autoantigen [65]. Some HLA 
variants are shown to convey protection for autoimmune diseases, while others make 
an individual more susceptible. The HLA molecules are responsible for antigen 
presentation at two critical time points; in the thymus during establishment of central 
tolerance and in the periphery during initiation of immune responses [66, 67]. There 
are also variants in several other genes with links to autoimmune diseases. These are 
typically genes encoding different parts of the immune regulation such as co-
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stimulatory molecules, cytokines, contributors of the different signaling cascades, 
regulation of apoptosis and phagocytosis [68].  
Disregarding the monogenetic autoimmune diseases, genes alone are not enough to 
disturb the normal immune regulation. Different environmental factors have been 
suggested as possible disease triggers. In the case of an infection, the pathogen 
activates both the adaptive response through presentation of antigen and also 
stimulates the innate secretion of cytokines and expression of co-receptors. If this 
happens in the presence of autoreactive cells it might be the initiating factor of the 
autoimmune process, known as bystander activation [69, 70]. This issue will be 
discussed further in the following sections. Tissue damage could also provide 
adjuvant for the autoreactive T cells as damage-associated molecular patterns 
(DAMPs), as well as increasing the presence of self-antigens. [71]. The process of 
molecular mimicry is another suggestion of how infections can induce an 
autoimmune reaction. This occurs when foreign antigens share structural similarities, 
charges and sequences as antigens from self, and the activated T cells or antibodies 
cross-react with self [72, 73]. Other environmental factors, such as smoking, 
exposure to toxins, estrogens and silicone implants have also been discussed in 
relation to autoimmune diseases [74-76].  
1.4.1 Viral infections, type I IFN production and autoimmunity 
When addressing the role of viral infections in autoimmune diseases, we must 
consider the antiviral immunity and interferon production explained previously. If a 
virus infects a host cell, ISGs are induced leading to production of interferons and 
ultimately viral clearance. However, in recent years it has been shown that IFN-α/β 
also can be harmful during a viral infection by activating an inflammatory reaction 
leading to tissue damage that worsens the disease picture [77]. It’s been shown that 
IFN-α can induce increased expressions of autoantigens, such as Ro52, seen in 
Sjögren’s syndrome (SS) and systemic lupus erythematosus (SLE) [78] and that 
autoantibodies in combination with material released by apoptotic cells can increase 
production of type I IFNs by pDC [79]. Increased IFN serum levels have been 
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reported in patients with SLE [80] suggesting IFN involvement in disease pathology, 
and recently type I IFN activity was also shown to be increased in the organ specific 
disorders Hashimoto’s thyroiditis (HT), Graves’ disease (GD) and type 1 diabetes 
(T1D) [81, 82]. In addition, there has also been several reports were treatment of 
chronic viral infections using interferon therapy has induced autoimmune disease 
development or worsening of existing disease [83, 84] 
 
1.5 Autoimmune Addison’s disease  
Autoimmune Addison’s disease (AAD) is a classic example of an organ specific 
autoimmune disease. The organ affected is the adrenal glands, and the disease and 
clinical symptoms was first described in 1855 by Thomas Addison after investigating 
the adrenals of 11 deceased patients [85]. At that time tuberculous adrenalitis was a 
major cause of Addison’s disease, as it still is in the developing countries today [86, 
87]. However, presently in the western world, autoimmune adrenalitis accounts for 
80-90% of the cases [88-90]. The prevalence of Addison’s disease in Norway is 
estimated to be 144 per million [88], the same number varying from 93-117 in other 
developed countries [91-93] making it one of the more rare autoimmune disorders. 
The incidence in the Norwegian study was found to be 4.4 per million [88]. Like 
most autoimmune diseases it has a female preponderance (from 55 to 77%) and the 
clinical symptoms normally presents between 30 and 50 years of age, although it can 
occur at all ages [91, 92, 94, 95]. 
1.5.1 The adrenal glands 
The adrenal glands are one of several endocrine organs of the body. They are located 
on top of the left and right kidney, and consist of the adrenal cortex and the adrenal 
medulla, separated both in function and structural appearance.  The medulla is the 
core of the gland (Figure 4) and its chromaffin cells produces catecholamine 
hormones that are released as a result of stimulation of the sympathetic nervous 
system, a stress response. The specific hormones released are adrenaline 
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(epinephrine) and noradrenaline (norepinephrine), responding to stress by increasing 
the heart rate and blood pressure [96]. The medulla is surrounded by the adrenal 
cortex, which is the affected tissue in AAD. 
The adrenal cortex is divided into three zones based on their histological picture 
(Figure 4). The three zones produce different groups of steroid hormones, all derived 
from cholesterol. The layer closest to the medulla is entitled zona reticularis, the 
middle layer is zona fasiculata and the outermost layer is zona glomerulosa [97]. 
Zona golmerulosa secretes the mineralocorticoid aldosterone, which affects the 
kidney through the mineralocorticoid receptor and plays an important part in 
regulating the salt and water balance, and thereby the blood pressure. The cells of 
zona fasciculata secrete the glucocorticoids, the most important being cortisol, as a 
direct response to adrenocorticotropic hormone (ACTH) secreted by the pituitary 
gland. The release of ACTH is again regulated by corticotropin-releasing hormone 
(CRH) secreted from the hypothalamus. The cortisol then signals the hypothalamus to 
shut down production in a negative feedback manner and the whole process together 
is entitled the hypothalamic-pituitary-adrenal (HPA)-axis [98]. Cortisol is a vital 
hormone with diverse effects on almost all cells and tissues of the body regulating 
and assisting in metabolism, cardiovascular function, blood pressure and immune 
responses. Zona reticularis produce adrenal androgens, such as androstenedione, 
dehydroepiandrosterone (DHEA) and 17-hydroxyprogesterone. Little is known about 
their physiological role, but they are believed to function as prohormones for 
production of active androgens and/or estrogens in other tissues [99].  
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Figure 4: Schematic overview of the adrenal gland.  The adrenal gland is divided into the adrenal 
medulla and the adrenal cortex. The cells of the medulla produce and secrete catecholamines, while 
the cells of the adrenal cortex produce vital steroid hormones. The adrenal cortex is separated in three 
different layers; furthest out is the zona glomerulosa, followed by the zona fasciculata and the zona 
reticularis which is located closest to the medulla. Figure produced using Servier Medical Art 
(http://www.servier.com/Powerpoint-image-bank). 
1.5.2 Clinical and histological picture in AAD 
After initiation of the disease the three layers of the adrenal cortex is gradually 
destroyed by immune responses, leaving only a fibrous tissue. A normal healthy 
adrenal is around 4-6 cm long, 2-3 cm wide and 3-6 mm thick [100], while they 
shrink in size in diseased individuals. Histopathological surveys of deceased AAD 
patients reveal a widespread infiltrate of mononuclear cells including lymphocytes, 
plasma cells and macrophages [101, 102]. AAD has a subclinical disease 
development, the properties of the adrenals allows them to produce adequate amounts 
of hormones up until 10% of functional adrenocortical cells remain [103], and then 
the clinical symptoms will start to show. These patients have a variety of clinical 
symptoms, such as fatigue, weight loss, nausea and vomiting, which are vague and 
hard to diagnose. Some clinical symptoms are much more specific and characteristic 
of Addison’s, for instance hyperpigmentation of the skin and mucosal surfaces caused 
by the elevated levels of ACTH and salt cravings [90]. It wasn’t until the late 40’s 
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that a sustainable treatment option for Addison’s, synthetic glucocorticoids, was 
introduced in medical care, before that time the diagnosis was fatal [104].  
1.5.3 AAD in autoimmune polyendocrine syndromes 
AAD may occur isolated, or it could present alongside other known autoimmune 
diseases in an autoimmune polyendocrine syndrome (APS) seen in about 50-60% of 
the cases [88, 90, 105]. APS-1 has already been mentioned as an example of rare a 
monogenic autoimmune disease, and is defined by the presence of at least two of the 
following; AAD, primary hypoparathyroidism or mucocutaneous candiasis [106, 
107]. AAD is the least common of the three, even though it occurs in up to 80% of 
adult APS-1 patients [108]. The disease onset is usually during childhood, much 
earlier than for most patients with isolated AAD [109]. APS-2 is a more common 
autoimmune polyendocrine syndrome, defined as having AAD in combination with 
autoimmune thyroid disease and/or T1D [110, 111]. However, the presence of other 
autoimmune diseases such as gonadal failure, vitiligo, pernicious anemia and alopecia 
also occurs [112]. A third syndrome with AAD is also classified, APS-4, including 
AAD and other autoimmune diseases, while excluding thyroid disease and T1D 
[112].  
1.5.4 Steroid cytochrome P450 21-hydroxylase (21OH) and AAD 
Autoantibodies against steroid cytochrome P450 21-hydroxylase (21OH) are present 
in more than 90% of recently diagnosed patients with AAD, declining somewhat in 
patients with longstanding disease [113, 114]. The presence of circulating antibodies 
against the adrenal cortex has been known since the late 50’s, but the identity of 
21OH was not known until 1992 [115]. 21OH is an intracellular enzyme specifically 
expressed in the adrenal cortex. It is the dominant autoantigen in AAD, and today 
autoantibodies against it are used for diagnostic purposes [114]. Autoantibodies 
against 21OH may be detected in individuals with other autoimmune diseases like 
hypoparathyroidism, in members of families with an accumulation of autoimmune 
diseases, and also in less than 0.5% of the healthy population [116, 117]. Therefore, 
having 21OH autoantibodies does not mean that you will develop AAD for certain, 
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however the levels of autoantibodies correlates with the risk of disease development 
[118] and it is a valuable disease predictive marker if AAD is suspected.  
It is not known whether the antibodies against 21OH play a role in the development 
of AAD, or if they are just products of the immune mediated adrenal destruction. One 
study measured the IFN-γ production in cells from AAD patients stimulated with 
21OH, and found that it was enhanced in the presence of 21OH-specific 
autoantibodies, indicating that the antibodies could work as adjuvants augmenting the 
immune reaction against the adrenals [119]. Also, it was recently shown that a 
woman with newly diagnosed Addison’s disease and high 21OH antibody titers 
experienced sustained improvement and were able to discontinue steroid treatment 
after Rituximab treatment for B cell depletion [120].  
1.5.5 Genetic predisposition 
As with autoimmune diseases in general, there are genes that are associated with 
AAD. The HLA associations have been intensively studied, and certain class II 
alleles, such as HLA-DR3 and DR4, have been linked to AAD [121]. The more 
specific haplotypes are HLA-DRB1*0301-DQA1*0501-DQB1*0201 (DR3/DQ2) 
and DRB1*04-04-DQA1*0301-DQB1*0302 (DR4.4/DQ8) [88, 113, 122]. An 
association between AAD and MHC class I have also been reported, more 
specifically to HLA-B*08 [123] and HLA-B*08 in combination with DR3 [124]. The 
MHC region is located on chromosome 6 as well as two other genes that are 
mentioned in connection with AAD, MHC class I related chain A (MIC-A) and the 
gene encoding 21OH (CYP21A2). Variants in both convey increased susceptibility 
when they are present together with DR3/DQ2 and DR4.4/DQ8, but MIC-A has also 
been described as an independent risk factor in some studies [123, 125, 126].  
Several non-MHC susceptibility genes have also been reported for AAD, of which 
protein-tyrosine phosphatase non-receptor type 22 (PTPN22) is a well-studied 
example [127, 128]. This gene and its specific single nucleotide polymorphism, 
1858C>T (rs2476601) substituting arginine with tryptophan in position 620, has been 
described for several autoimmune diseases, including rheumatoid arthritis (RA), T1D, 
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SLE and GD [129-132]. This is an enzyme expressed in hematopoietic cells, 
specifically T cells, B cells, DCs and macrophages which regulate immune signaling 
through antigen receptors (the TcR) and pattern recognition receptors [133, 134]. It’s 
been debated whether the disease variant is a gain of function or not, and it is likely 
involved in several stages of autoimmune disease development. The disease variant 
has been shown to alter the responsiveness of mature T cells and to cause failure in 
upregulation of type I IFN production after TLR signaling [134, 135]. 
1.5.6 Viral infections as a trigger of AAD 
As mentioned previously, viral infections and the interferons induced by infections 
have been implicated for several autoimmune diseases. There are also reports 
regarding viral infections, interferons and AAD, suggesting that this could be 
important factors in the disease development. Adrenalitis as a result of a viral 
infection by herpes simplex [136], hepatitis B [137], Epstein-Barr [138], 
cytomegalovirus [139] and human herpesvirus-6 [140] have been reported. These are 
all examples of persistent viruses giving constant presence of viral antigens. This 
could drive a long term immune response resulting in autoimmunity [70]. 
Alternatively, they could be initial triggers of autoimmunity, involved in the early 
phase. Viral association to AAD have also been shown indirectly in cases where 
recombinant IFN-α is used as treatment for chronic viral infections and have led to 
induction of autoantibodies against 21OH [141, 142], and have resulted in short 
periods of transient adrenal insufficiency [141]. IFN-α therapy have also led to a 
worsening of symptoms in a patient already diagnosed with AAD [143]. A case 
report links hepatitis C viral infection to subclinical adrenal insufficiency where the 
condition  actually worsened after recombinant IFN-α therapy [144]. 
1.5.7 Cytomegalovirus and Addison’s disease 
Since several different viruses have been reported in relation to AAD, it doesn’t seem 
likely that there is just one single perpetrator. However, cytomegalovirus (CMV) is a 
good candidate due to its high infection rate, the great variation in CMV antigens that 
could be presented, and the broad CD8+ T cell response it induces [145, 146]. Human 
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CMV is a herpes DNA virus which after primary infection will establish a lifelong 
latent infection, with the possibility for periodical reactivation and shedding of 
infectious virus [147]. Antibodies against CMV as a result of a previous infection are 
present in around 50-60% of the adult population in developed countries [148-150]. 
CMV infects various parts of the body, and is also able to infect and replicate in 
adrenocortical cells [151]. 
There have been several reports of Addison’s disease development in patients with a 
human immunodeficiency virus (HIV) infection or acquired immunodeficiency 
syndrome (AIDS) that are infected by CMV, however this is not considered of 
autoimmune ethology but rather a direct cytopathic effect by CMV on the adrenal 
cells [152]. Nevertheless, there also exist reports were CMV infection alone is 
proposed as the initiating factor of AAD development [153].   
1.5.8 Proposed pathogenesis of AAD induced by virus infection 
Several factors are involved during development of an autoimmune disease, and since 
AAD is an organ specific disease, it is reasonable to assume that the tissue itself is 
important, and also has a role to play. The cells of the adrenal cortex have several 
properties that could support viral infections as triggers or inducers of autoimmune 
disease in predisposed individuals. For instance, they express TLR3, as well as 
several other TLRs and produce important inflammatory cytokines such as IL-1, IL-
6, IL-18 and TNF-α [154-156]. In resolving a potential viral infection of the adrenals 
lymphocytes need to enter the affected tissue. This is achieved through secretion of 
chemokines such as CXCL10 and adhesion molecules by tissue resident cells [157]. 
CXCL10 is reported to be elevated in sera from AAD patients [158-160]. This 
chemokine could be produced by activated immune cells, or potentially by cells of 
the adrenal cortex. This has been shown in a study of autoimmune thyroid disorders, 
where the thyroid follicular cells of the target tissue produced CXCL10 [161]. This 
was also demonstrated for primary adrenal zona fasiculata cells which secreted 
CXCL10 after stimulation with the cytokines IFN-γ and TNF-α [162] and in an 
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adrenocortical carcinoma cell line stimulated with a viral dsRNA substitute both 
alone and in synergy with IFN-γ and TNF-α [159].  
However, recruiting lymphocytes to the adrenal during a viral infection is probably 
not enough to sustain an inflammatory environment for so long that more than 90% 
of the adrenocortical cells are destroyed during that period. The lymphocytes 
recruited could potentially be autoreactive, and their activity could be affected by 
interacting with the adrenal cells. An experiment investigating the autoimmune 
development in non-obese diabetic (NOD) mice showed a selective avidity 
maturation of the infiltrating T-lymphocyte population, suggesting a preferential 
expansion of T cells binding strongly to self, versus T cells with low-affinity TcRs 
[163]. The main antigen recognized by autoreactive T cells in AAD is believed to be 
21OH, since it’s exclusively expressed in the adrenal cortex and because of the 
presence of 21OH antibodies in these patients. Several studies support this notion, 
showing that T cells from AAD patients proliferate and produce IFN-γ after 
stimulation with 21OH peptides and full length protein, and demonstrating specific  
CD8- and CD4-restricted epitopes [119, 164, 165].  
With these properties in mind, the proposed mechanism of tissue destruction and 
disease development as a result of an acute or latent viral infection (adapted from 
Bratland and Husebye, Groom and Luster, and Fujinami et al. [54, 70, 166]) is as 
follows;  
 
Viral infection and initial immune activation in the adrenal cortex:  
In a genetically predisposed individual infected by a virus able to infect and replicate 
in the adrenocortical cells, TLR3 senses the infection through binding of double 
stranded RNA (dsRNA) produced by most viruses during their replication cycle 
[167]. TLR3 activation could in turn lead to IFN production and activation of ISGs 
such as CXCL10 and upregulation of MHC class I, as explained previously. 
Destruction of infected cells, either by the infection itself or by the innate immune 
response, releases cellular components (including 21OH) into the extracellular 
environment. The cellular content is ingested by DCs or macrophages shown to be 
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abundant in the adrenal cortex [168], and presented as antigens bound to MHC class 
II. If the virus is intact it could then infect the DC and be presented bound to MHC 
class I, or exogenous antigens could be cross-presented by MHC class I [169, 170]. 
Antigen presentation and activation of lymphocytes in the lymph node:  
The DCs migrates to the nearest lymph node were they activate potentially 
autoreactive naïve CD4+ and CD8+ T cells. IFN-γ is produced as a result of T cell 
activation, which further activates the APC to release cytokines important for 
differentiation into CD4+ effector T cells (Th1), such as IL-12. Activated CD4+ Th1 
cells are important helpers in the activation and clonal expansion of potentially 
autoreactive B cells and CTLs. The B cells then produce 21OH autoantibodies that 
can augment the inflammatory reaction. The activated effector cells upregulate 
expression of the CXCR3 receptor, and migrates to the infected tissue in response to 
the elevated levels of CXCL10. 
Autoimmune destruction of the cells in the adrenal cortex:  
Autoreactive CTLs exert a cytotoxic effect on the adrenal cells by recognizing 21OH-
derived peptides in the context of MHC class I presented on the cell surface. This has 
been shown in vitro by co-culturing 21OH-specific CD8+ T cells with the human 
adrenocortical carcinoma cell line NCI-H295R, resulting in increased levels of the 
degranulation marker CD107 and excessive production of granzyme B [164]. The 
CD4+ Th1 cells secrete IFN-γ and TNF, which can stimulate macrophages to release 
inflammatory cytokines (TNF and IL-1β), nitric oxide (NO) and other toxic oxygen 
species which destroy the infected tissue without excluding healthy cells [171]. This 
may enhance the presence of more potentially harmful antigens able to activate 
autoreactive CTLs and CD4+ Th1 (self-specific T cells), which in turn may perpetuate 
the autoimmune destruction. We know that the adrenocortical cells also are able to 
produce inflammatory cytokines upon stimulation, and that IFN-γ and TNF-α can 
stimulate the adrenocortical cells along with the tissue resident DCs and macrophages 
in order to secrete CXCL10. This gives rise to an inflammatory loop were the 
recruited lymphocytes produce more IFN-γ, leading to secretion of more CXCL10 
which again lead to a recruitment of more lymphocytes. Eventually the inflammation 
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burns out when all adrenocortical cells are destroyed, and there is no longer presence 
of 21OH antigens. 
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2. Aims of the study 
The overall objective 
Our main hypothesis was that adrenocortical cells in AAD are destroyed by cytotoxic 
T cells, specific for 21OH, responding to a viral infection and interferon production 
locally in the adrenals. The principal aim was therefore to elucidate pathogenic 
mechanisms of immune-mediated destruction of the adrenal cortex in AAD. 
The specific aims were 
I. To investigate the role of IFNs in AAD disease development including 
their effect on adrenocortical cells. 
II. To investigate the interferon induced CXCL10 production in patients 
with AAD. 
III. To investigate humoral and cellular immunity to cytomegalovirus in 
patients with AAD.  
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3. Comments to methodology  
While a detailed description of the materials and methods is part of each separate 
paper, this section will elaborate on some of the methods chosen and details not 
included in the papers. 
 
3.1 Choice of material 
Patient material (Paper I-III) 
Through the Norwegian registry and biobank for organ-specific autoimmune diseases 
(ROAS) we have access to serum, plasma, EDTA blood, DNA and peripheral blood 
mononuclear cells (PBMCs) from patients with confirmed AAD. Samples from this 
biobank were used in all three papers, and the exact amount is specified in the 
individual paper. The samples were consecutively chosen and the different patients 
overlap some in the different studies. All patients signed informed consent approved 
by the Health Region West Ethics committee (149/96-47.96) and the experiments 
were conducted in accordance with the declaration of Helsinki. 
Healthy controls (Paper II and III) 
Heparinized blood samples from gender- and age-matched healthy controls used in 
these studies were collected from blood donors provided by the blood bank at 
Haukeland University Hospital. It was either used directly, or PBMC and plasma 
were isolated using Ficoll-Paque Plus and frozen at -150ºC or -80ºC, respectively. 
The number of controls used is specified in the individual paper. All controls signed 
informed consent approved by the Health Region West Ethics committee.  
Cell culture experiments (Paper I) 
For both practical and ethical reasons we did not have access to primary 
adrenocortical cells or adrenocortical tissue. Thus the decision was made to use the 
human adrenocortical carcinoma cell line NCI-H295R. This cell line is well 
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established and has been shown to exert many of the same properties as primary 
adrenocortical cells [172]. For this study it was important to investigate whether these 
cells express the IFN-α/β and IFN-λ receptors and if the same receptors are present in 
human adrenal tissue. Thus slides mounted with 5 μM sections of human adrenal 
tissue were purchased from Abcam and used for immunohistochemistry staining.   
 
3.2 Methodological considerations 
Enzyme-linked immunosorbent assay (ELISA) for chemokine measurements (Paper I 
and II) 
For paper II two different ELISAs were used when investigating chemokine levels in 
serum and cell supernatant respectively. The serum concentrations were measured in 
an ELISA kit from RayBiotech validated for serum/plasma analysis, with a broader 
standard curve than the ELISA used for cell supernatants. For the cell supernatant 
measurements the same ELISA kit from R&D systems was employed for both 
stimulated PBMC of paper II and NCI-H295R cells of paper I.   
PBMC stimulation experiments (Paper II) 
When investigating the chemokine and interferon production in cells stimulated with 
cytokines or polyinosine-polycytidylic acid (poly (I:C)), the published results are 
from experiments performed directly after thawing and washing of the PBMC 
without resting the cells. AAD patients receive cortisol replacement therapy, and thus 
the glucocorticoids may interfere with the IFN signaling pathway. By resting the cells 
for 24h any interference caused by the glucocorticoid could possibly have been 
avoided. To test this additional experiments were performed on cells rested 24h prior 
to stimulation, but in general this did not improve the chemokine production. 
RNA was isolated and quantitative real-time polymerase chain reaction (qRT-PCR) 
was performed on cells that had been stimulated with cytokines and poly (I:C) for 
24h. Ideally it would have been better to investigate the mRNA expression at an 
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earlier time point since the expression levels of some ISGs are at its highest after 
about eight hours [173]. But wanting also to investigate the chemokine and interferon 
secretion in cell supernatant, 24h was preferred since limited amounts of patient 
PBMC made it difficult to harvest cells at multiple time points.  
Bioassay for type I IFNs (Paper II) 
The cell supernatant from the stimulation experiments was used for two different 
chemokine ELISAs in addition to measuring the type I IFN production. Due to 
limited material a bioassay based on the reporter cell line, HEK Blue IFN-α/β from 
Invivogen was employed, where only 20 μl of the cell supernatant was needed. This 
cell line has a functional type I IFN pathway, and in the presence of IFN-α/β it will 
turn on the expression of a secreted embryonic alkaline phosphatase (SEAP). Cell 
supernatant was incubated with the HEK blue cells in a 96 well plate for 24h, then the 
induced HEK Blue IFN-α/β supernatant were mixed with QUANTI-Blue, a medium 
that turns from red to blue in the presence of SEAP. The absorbance was measured 
and IFN-α/β production was calculated in relation to a standard curve with known 
IFN concentration. 
PTPN22 SNP analysis (Paper II) 
The SNP analysis was performed as described previously [129]. However, since 
DNA was not available from the healthy controls, only patients were included in this 
analysis.  
STAT1 and STAT2 activation levels of stimulated PBMC (Paper II) 
The STAT1 and STAT2 cell-based ELISA immunoassays were included as a follow-
up experiment in paper II, based on the results obtained in the PBMC stimulation 
experiments. However, PBMC from patients and controls employed in the initial 
stimulation experiment were no longer available, consequently the STAT 
experiments were performed on PBMC from new subjects. A cell-based assay was 
chosen to measure levels of total STAT and STAT activation, allowing use of the 
same sample on the two different kits simultaneously, thus limiting the need for 
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cellular material. The cell-based ELISA was also a very quick and efficient method 
compared to for instance flow cytometry analysis. 
CMV peptide specific dextramer analysis (Paper III) 
The MHC dextramer technic from Immudex was used to investigate the presence of 
T cells specific for HLA-B8 and HLA-A2 CMV restricted epitopes. This technic 
from Immudex allows fast and reliable measurements of T cell specificity considered 
to be better than the traditional MHC tetramer staining procedures [174, 175].  
 
Figure 5: The MHC dextramer technic from Immudex. The MHC Dextramer reagent is a 
fluorescent labeled MHC multimer. It can be used to detect T cells specific for the antigen the MHC 
multimer is loaded with. The dextran polymer backbone is loaded with an optimum number of MHC 
and fluorochrome molecules, allowing the dextramer to interact with several TcR on the individual T 
cell giving a stable interaction and a high staining intensity. The dextramers can be used to detect 
antigen-specific T cells in fluids using flow cytometry. Image from http://www.immudex.com/about-
products/dextramer-descrip.aspx 
MHC dextramers consisting of recombinant HLA-A2 and HLA-B8 loaded with their 
respective cognate CMV peptides (HLA-A*0201/NLPMVATV/PE and HLA-
B*0801/QIKVRVDMV/PE) were purchased from Immudex, along with negative 
control MHC dextramers loaded with HIV gag-derived peptides (HLA-
A*0201/SLYNTVATL/PE and HLA-B*0801/DIYKRWII/PE) and used to test for 
CMV specific CD8+ T cell responses, both in cells ex vivo and after stimulation with 
CMV peptides.  
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4. Summary of papers 
Paper I 
In paper I the aim was to study the possible immunopathological effect that type I and 
III IFNs could inflict on adrenocortical cells, and if these effects could play a role in 
the disease development of AAD. All experiments were conducted with the human 
adrenocortical carcinoma NCI-H295R cell line (H295R). The presence of the 
IFNAR1 and IFNλR1 chains on the H295R cells, part of the two IFN binding 
receptors, were confirmed both by flow cytometry and immunofluorescence. The 
same receptor components were also shown to be present in healthy human adrenal 
cortex tissue by immunohistochemistry staining.  
Stimulation with recombinant IFN-α, IFN-β, IFN-λ and poly (I:C) were shown to 
exert cytotoxic effect on the H295R cells, by measuring lactate dehydrogenase (LDH) 
release to evaluate their membrane integrity. The effect was greatest when 
stimulating with poly (I:C), while using poly (I:C) in combination with the IFNs gave 
a significantly higher LDH release compared to IFNs alone.  
Stimulation with type I and III IFNs significantly increased the expression of MHC 
class I on the H295R cells measured by flow cytometry, while this upregulation was 
at its highest after type II IFN stimulation. Poly (I:C) alone did not significantly 
increase the MHC class I upregulation, although it was elevated compared to 
unstimulated control. The mRNA expression of CYP21A2 was measured on RNA 
isolated from the cell pellet from the stimulation experiment using qRT-PCR. The 
21OH expression increased two- to threefold after stimulation with type I/III IFNs 
and poly (I:C) compared to unstimulated cells. 
The H295R cells ability to produce CXCL10 and the related chemokines CXCL9 and 
CXCL11 was measured by ELISA in cell supernatant from stimulation experiments 
with type I and III IFNs. Alone the type I/III IFNs did not induce significant levels of 
chemokine, but in combination with IFN-γ or poly (I:C) the expression of CXCL10 
was considerably increased compared to the levels induced by IFN-γ and poly (I:C) 
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alone. This suggests that there is a synergistic effect of type I/III IFNs on both IFN-γ 
and poly (I:C). CXCL11 was not produced at the same levels by the H295R cells, and 
for CXCL9 only IFN-γ appeared to have some effect. In a migration experiment the 
CXCL10 produced by IFN-γ and poly (I:C) stimulation was sufficient to increase the 
migration of 21OH specific T cells towards the chemokine in the H295R cell 
supernatant using a trans well system, compared to the migration induced by 
unstimulated cells.  
Paper II 
In paper II the source of the increased serum CXCL10 and CXCL9 concentrations in 
AAD patients was investigated by studying their propensity to produce chemokines 
after IFN stimulation. Previous studies have reported elevated serum chemokine 
levels in AAD patients, which were confirmed in our patient cohort by CXCL10 and 
CXCL9 ELISA. In an attempt to discover the source of this production PBMC from 
AAD patients and controls were stimulated with type I and II IFNs and poly (I:C). In 
all cases the patients were found to produce significantly lower levels of CXCL10 
and CXCL9 after a 24h stimulation period, compared to healthy controls as measured 
by ELISA. 
The expression of two ISGs, USP18 and IRF7, was also measured in relation to IFN 
stimulation and the relative mRNA expression of USP18 was found to be decreased 
in the patients for all stimuli. For IRF7 there were no significant differences after 
cytokine stimulation, while poly (I:C) induced a significantly lower expression in the 
patients, indicating a poorer IFN production after TLR3 stimulation. The poly (I:C) 
induced production of IFN-α/β collectively was also measured using a bioassay, and 
found to be significantly decreased in the patients.  
To investigate the results further the data was correlated against a SNP in the 
PTPN22 gene associated with AAD, which have been found to confer an impaired 
IFN response after TLR stimulation. This was investigated in the patient cohort were 
DNA was available. The poly (I:C) induced CXCL10 production was stratified 
between patients carrying the disease associated SNP and those that were 
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homozygous for the normal variant, and the disease associated carriers produced 
significantly lower amounts of CXCL10. This effect was not observed for CXCL9.  
The total and phosphorylated STAT1 and STAT2 levels was also investigated in 
relation to cytokine and poly (I:C) stimulation, but no significant differences between 
patients and controls in that part of the signaling pathway was found.   
In a parallel experiment the relative mRNA expression in CD4+ T cells of five ISGs 
was measured in a new set of patients and controls, to examine if they displayed an 
activated IFN signature in their peripheral blood. However, although selected patients 
showed signs of IFN activation, no significant differences between patients and 
controls were detected.  
Paper III 
In order to investigate the virus hypothesis further the cellular and humoral response 
to cytomegalovirus was examined in AAD patients and controls in paper III. A 
primary or reactivating CMV infection was hypothesized as a possible environmental 
factor in AAD development. With HLA-B8 being a risk allele in AAD, CD8+ T cell 
response to HLA-B8 restricted epitopes was investigated in addition to an epitope 
restricted to the more common class I HLA-A2 subtype. 
Initially the IgG and IgM CMV antibody levels were determined in patients and 
controls. No statistically significant differences were found between the two groups, 
but the percentage of CMV IgG positive was a bit higher in the patient cohort. Only 
seropositive patients and controls were included when investigating CMV-specific T 
cell response.   
No ex vivo differences could be detected between patients and controls regarding the 
function or frequency of CMV-specific T cells using dextramers to detect CMV 
specific T cells by flow cytometry and IFN-γ ELISpot to measure activity. However, 
a difference was detected in the level of total CD8+ T cells, which were significantly 
lower in the patient cohort. The cells were also stimulated with CMV epitopes in 
vitro while expanding them over a period of 13 days, but again no significant 
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differences could be measured. The level of degranulation of CMV stimulated cells 
was investigated using a CD107a based degranulation assay, without finding any 
differences.  
Although there were no significant differences towards CMV looking at the group as 
a whole, individual patients showed signs of reactivating CMV infection by 
fluctuating positive IgM levels over a time period in addition to poor CD8+ T cell 
responses to the HLA-B8 restricted CMV epitope.  
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5. Discussion 
Autoimmune Addison’s disease is an example of a classic organ specific autoimmune 
disease with an unknown etiology. There’s been conducted a lot of research with 
focus on the genetic aspects of the disease, but with this thesis we wanted to 
investigate the environmental basis of the disease development and the role played by 
the adrenal cortex itself. Due to the slow evolvement of the genetic landscape, the 
increasing incidence of autoimmune diseases could hardly be explained by genetics 
alone, and thus from 1997 the research focus and publications on the environmental 
factors of autoimmunity have grown on average 7% each year [176]. In this regard 
we propose a hypothesis that for individuals genetically predisposed to AAD, this 
environmental factor could be a viral infection. The virus could serve as a 
precipitating event in the autoimmune process leading to the disease, while the 
adrenal cortex itself could be responsible for recruiting lymphocytes and maintaining 
the inflammatory environment essential for disease development.  
 
5.1 The target tissue 
The cells of the adrenal cortex exert certain properties that would allow an immune 
response to take place, such as expression of different types of TLR [154, 177]. In 
addition, the cells of the adrenal cortex are able to produce different cytokines and 
chemokines as response to various stimuli (Introduction section 1.5.8). In paper I we 
wanted to investigate how the target tissue would respond to the presence of viral 
induced interferons, and due to lack of primary adrenocortical cells, we used the well-
established adrenocortical carcinoma cell line H295R. To test this, we firstly needed 
to explore the presence of their receptors, which we confirmed with both flow 
cytometry and immunofluorescence. More specifically we detected the receptor 
components, IFNAR1 and IFNλR1. We also were able to detect the same components 
on human adrenal tissue slides using immunohistochemistry. Previous studies have 
shown that IFNλR1 mRNA expression is detected in the adrenal gland, while 
IFNAR1 is known to be expressed in different adrenocortical cell lines, including 
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H295R cells [40, 178, 179]. Confirming that the IFN-α/β and the IFN-λ receptors are 
expressed both in adrenal tissue and in the cell line, allowed us to use the H295R 
cells as a model for studying virus induced AAD development. 
Interferons cytotoxic to adrenocortical cells 
Production of interferons after a viral infection is important for induction of ISGs, but 
the interferons themselves have also been shown to induce cell death both alone or in 
combination with viral infections or poly (I:C) [180-183]. Thus the interferons 
produced in response to an infection could end up being harmful for the affected 
tissue. In paper I we observed that stimulating the adrenocortical cells with type I and 
III IFNs alone or in combination with poly (I:C) exerted significant cytotoxicity of 
the cells, suggesting that the interferons could play an important destructive role on 
the cells of the adrenal cortex as well, in addition to contributing to the inflamed 
environment.  
Upregulation of HLA class I and 21OH after interferon stimulation 
In paper I we found that stimulation of the adrenocortical cells with type I/III IFNs 
alone or in combination with IFN-γ upregulated expression of HLA class I. 
Upregulation of HLA class I is important for recruiting CTL to the site of infection, 
allowing for a CTL mediated destruction of infected cells, and a similar upregulation 
has been shown to correlate with the disease onset in a mouse model of virus induced 
T1D [184, 185]. The results in paper I show that adrenocortical cells are prone to IFN 
induced upregulation of HLA class I, and we envision a similar response in the cells 
of the adrenal cortex after a viral infection. In T1D hyperexpression of HLA class I is 
considered a normal trait in insulin containing islets [186]. In addition to HLA class I 
upregulation, the mRNA expression of 21OH increased significantly after stimulation 
with type I/III IFNs and poly (I:C). If viral infections and interferons are able to 
induce the same response in the cells of the adrenal cortex, enhancing the expression 
of 21OH could lead to higher availability of potentially harmful antigens presented by 
hyperexpressed HLA class I to CTL recruited to the site of infection. These are both 
important factors supporting a role for the adrenal cells in the disease development.  
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The chemokine CXCL10 
CXCL10 have been shown to be elevated in sera of patients with different 
autoimmune diseases, such as autoimmune thyroiditis, SLE and T1D respectively 
[187-189]. This is also the case for AAD [160, 162], and we found both CXCL10 and 
CXCL9 to be significantly elevated in patient sera in paper II. The source of the 
elevated chemokine levels in AAD patients is not known; it could be produced 
locally due to an inflamed environment of the adrenal cortex or by activated 
lymphocytes or monocytes in the blood. Both H295R cells and adrenocortical cells 
have been shown to produce CXCL10 after stimulation with proinflammatory 
cytokines and poly (I:C) [159, 162], so we know that the cells of the adrenal cortex 
themselves are capable of this production. In paper II we found that in spite of having 
elevated chemokine levels in their sera, patient PBMC produced significantly lower 
levels of these chemokines after IFN stimulation compared to healthy controls. These 
results supports the notion that the adrenal cells themselves are in fact responsible for 
the chemokine production detected in patient sera, a view supported by similar 
studies [159, 162, 190].  
Interferons can induce infected or bystander cells to secrete CXCL10, and thus recruit 
activated T cells to the site of infection [54]. In paper I we demonstrated that 
adrenocortical cells stimulated with IFN (I/III) in combination with poly (I:C) and 
IFN-γ did in fact produce CXCL10, and that the level of secreted chemokines was 
able to attract 21OH specific T cells in a transwell assay in significantly higher 
amounts than supernatant from unstimulated H295R cells. This neatly demonstrates 
how a virus infection in the adrenals could lead to recruitment of T cells that are 
autoreactive against the 21OH it’s bound to encounter in the inflamed tissue.  
 
5.2 Interferons in AAD 
An interferon signature, or an increased expression of type I IFN regulated genes, 
have been reported in various systemic and endocrine autoimmune diseases, such as 
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SLE, SS and GD [191-193]. A similar signature has not yet been reported for AAD, 
and thus we wanted to investigate this in our patient cohort. Based on a previous 
study on AAD patients, we chose to look at the expression of five ISGs that was 
shown to be hypomethylated in CD4+ T cells from AAD patients [194]. However, 
though there were some patients who showed a clear upregulation of individual 
genes, there were no significant differences in the IFN score between AAD patients 
and healthy controls. The patients used in these studies were consecutively recruited 
and thus disease duration would vary. Two recently published studies showed an IFN 
signature in pre-diabetic patients [82, 195], suggesting that an IFN signature might 
have existed in these patients in a pre-AAD time point during the development of the 
disease.  
Even though we found no evidence of an IFN signature we still suspect that type I 
IFNs has a role to play in the development of AAD, due to the high levels of 
CXCL10 in sera and how type I IFN treatment have been shown to induce adrenalitis 
[141, 142]. In paper II we wanted to investigate if there were any differences in how 
AAD patients and healthy controls responded to interferons, by examining the 
chemokine release of their PBMC. While the patients have significantly higher 
amounts of CXCL10 and the related chemokine CXCL9 in their sera, their PBMC did 
actually produce significantly lower amounts of the same chemokines after 
stimulation with type I IFNs and IFN-γ. This was also the case when we stimulated 
the cells using poly (I:C), thus inducing IFN production through TLR3 stimulation. 
Therefore, the patient PBMC was not only deficient in their chemokine production 
after direct stimulation through their interferon receptors, but also when stimulated 
endogenously using a synthetic analog for dsRNA. It seemed evident that the failed 
chemokine induction was not just a result of poor activation of the IFN receptors, but 
also due to reduced IFN production, which was demonstrated when we measured 
type I IFNs after poly (I:C) stimulation and found significantly lower values in the 
patients.  
We did not only measure activation by chemokine secretion we also tested the 
mRNA expression of two well-known ISGs Ubiquitin-specific peptidase 18 (encoded 
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by USP18) and interferon regulatory factor 7 (encoded by IRF7) from the same cells. 
USP18 is a classic ISG that functions by downregulating the JAK-STAT pathway 
activated by the interferons [196], and the expression of USP18 was significantly 
lower in the patients for all stimulatory conditions which show that the impaired 
response to interferons is not only affecting CXCL9 and CXCL10 production. IRF7 
is a positive feedback regulator of the IFN response, induced to amplify the IFN 
production after for instance TLR3 stimulation (activated in our case by poly (I:C)) 
[197]. The IRF7 expression was significantly lower in the patients after poly (I:C) 
stimulation, however no differences were detected after IFN stimulation alone. The 
decreased chemokine production after direct exogenous IFN stimulation is 
independent of IRF7, while the endogenously IFN stimulated cells not only fail in 
interferon induced chemokine production but also interferon production itself. To try 
and elucidate why these patients appear to have a defective response to IFNs we 
looked into several possible explanations discussed below. 
Interferon signaling and activation of STAT1/2 
In order to find the reason of the impaired IFN response in the patient cells, we 
wanted to investigate whether there were any differences in the level of STAT1 and 
STAT2, and their phosphorylation activity in relation to the stimulation experiments. 
However, we found no differences either in total STAT1/2 or in regards to 
phosphorylation after IFN and poly (I:C) stimulation, indicating that the impaired 
chemokine production is a result of defects in events downstream of STAT signaling 
or during IFN production.  
The effect of glucocorticoid (GC) treatment 
Since AAD patients have no endogenous cortisol production, they receive cortisol 
supplementation therapy. This supplementation is meant to replace the normal 
cortisol production found in healthy individuals, and though there exists concern 
whether they receive too much [198] these patients do not appear to have increased 
serum levels of cortisol compared to healthy controls [199]. Still, GCs are known to 
exert several immunosuppressive functions [200] and this could in theory explain the 
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differences we observe in paper II. GC have been shown to inhibit STAT1 
phosphorylation after poly (I:C) stimulation [201], but when we investigated the 
phosphorylation of STAT1 after PBMC stimulation between patients and healthy 
controls we found no differences, indicating that the GC doses given to the selected 
patients do not interfere with the results. In addition we performed an experiment 
where we rested the cells for 24h before stimulation, to avoid GC interference, but no 
overall improvement of CXCL10 production was observed.  
Are AAD patients genetically prone to poor interferon production? 
The reason for the decreased chemokine and interferon production could be explained 
by the fact that the patients are genetically prone to such a phenotype. One example is 
related to a SNP in the PTPN22 gene associated with several autoimmune diseases, 
including AAD [128, 134]. A recent study showed that carriers of the disease allele 
1858T, had an impaired interferon production after TLR3 stimulation [135], which 
we also experienced in paper II in relation to poly (I:C) stimulation. We saw a 
significant difference in CXCL10 production between carriers of the 1858T allele and 
the normal C variant. However, there were no correlation between PTPN22-C1858T 
and CXCL9 production which is consistent with CXCL9 being induced primarily by 
IFN-γ and not by type I IFNs. A similar result was recently published on a cohort of 
SLE patients, where carriers of the disease associated allele produced significantly 
lower amounts of IFN-α after stimulation of the TLR7/8 receptor in pDC isolated 
from PBMC, even though there were no differences in IFN signature or IFN-α serum 
levels between carriers and non-carriers [202].   
If patients carrying this mutation have a poorer response to TLR activation than the 
patients with the non-mutated gene, it would seem that they could be more prone to 
infections, and also to prolonged viral persistence. Indeed there exist reports that 
AAD patients have increased risk of premature death, among others due to infections 
[203-205]. Patients with AAD have been shown to use higher amounts of 
antimicrobial agents, and have more infection related hospital admissions than the 
general public with no obvious correlation to their cortisol treatment [206]. However, 
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for the deficient immune response we report, only the poly (I:C) induced chemokine 
production would be affected by this mutation. The impaired CXCL10/9 production 
induced directly by exogenously added IFNs cannot be explained by the presence of 
the PTPN22 SNP, since PTPN22 is only involved upstream of endogenous IFN 
production. PTPN22 could therefore only explain the results partly. When excluding 
the T carriers there’s still a significant difference in IFN induced chemokine 
production between AAD patients and healthy controls further suggesting that the 
explanation lies somewhere downstream of the STAT phosphorylation step.  
 
5.3 Cytomegalovirus and Addison’s disease 
Since cytomegalovirus have a tropism for infecting the adrenals, in particular in 
immunocompromised individuals, it would seem reasonable to assume that CMV 
infection of the adrenals is not uncommon, but that the immune system is normally 
capable to clear or suppress the virus without a prolonged immune activation. 
However, in an individual that is genetically predisposed to AAD, the primary 
infection or the latent induction of the immune response it causes could be the 
precipitating event in the disease development. In paper III we tried to investigate 
whether AAD patients showed an increased propensity to CMV infections, and their 
CMV specific CD8+ T cell response. Over 70% of the patients had CMV positive IgG 
antibodies, which is consistent with reports from the middle-aged healthy population 
in the western world [207-209], although levels from the healthy controls tested in the 
same experiments with similar mean age was around 10% lower.  
In paper III we found that the ex vivo cellular response against CMV did not differ 
between patients and controls. We investigated the level and activity of CMV specific 
memory CD8+ T cells, both HLA-B8 and HLA-A2 restricted, without finding any 
significant differences. Similarly, no differences were detected after in vitro 
stimulation with CMV peptide and expansion of CMV specific CD8+ T cells were 
similar in patients and controls. However, we found a significant difference in the 
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level of total circulating CD8+ T cells in the patient cohort compared to the healthy 
controls. The AAD patients had significantly lower CD8+ T cell levels among their 
PBMC, consistent with similar reports in several autoimmune diseases including SLE 
[210], T1D [211], GD [212] and multiple sclerosis [213]. This CD8+ T cell deficiency 
is believed to be genetically determined, as first degree relatives to autoimmune 
disease patients also exert this trait [211, 214, 215]. It is possible that the CD8+ T cell 
deficiency, leads to an impaired viral clearance resulting in autoimmunity, which also 
could explain why infections appear to be more common in AAD patients, as 
discussed above. This prospect is described thoroughly in a review by M. Pender on 
Epstein-Barr virus (EBV) infection as the main culprit in genetically compromised 
individuals, where he suggests that a decreased CD8+ T cell level results in an 
impaired response to EBV, allowing possible autoreactive EBV-infected B cells to 
accumulate in the target organ  [216]. He does not exclude that other viral infections 
could be responsible for similar responses, however it might seem that EBV is more 
notoriously associated with autoimmune diseases than for instance CMV [217]. 
Although we didn’t find any significant differences in CMV immunity between the 
patients and controls in paper III, we did find some interesting observations in 
individual patients. One female patient in particular had positive CMV IgG levels 
over a time period of 12 years, while in that same period IgM levels went from 
negative, to positive, and then negative again suggesting a reactivation of infection. 
Interestingly this patient, who is HLA-B8 positive, had among the lowest observed 
levels of CMV specific CD8+ T cells. In paper II we found that this exact same 
patient had next to no chemokine production after type I interferon and poly (I:C) 
stimulation, but showed clear signs of an activated interferon signature in three of the 
five ISGs tested. Furthermore, the daughter of this patient also had AAD and, similar 
to the mother, had almost no detectable CMV-specific CD8+ T cells in spite of being 
anti-CMV IgG positive. We speculate that the co-occurrence of AAD and poor 
cellular immunity to CMV in this family is part of an inheritable extreme 
immunological phenotype that makes individuals more prone to develop 
autoimmunity with suboptimal control of viral infections. 
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6. Conclusions 
In accordance with the specific aims of this thesis, the following conclusions may be 
drawn: 
x Type I and III IFNs alone or in combination with IFN-γ and/or poly (I:C) are 
cytotoxic to H295R cells and leads to upregulated expression of MHC class I 
and 21OH. The type I/III IFN receptors are expressed both in human 
adrenocortical tissue and H295R cells.  
x 21OH specific T cells are able to migrate towards CXCL10 secreted by IFN 
and/or poly (I:C) stimulated H295R cells. 
x AAD patients have elevated serum levels of CXCL10 and CXCL9 while their 
PBMC have impaired CXCL10 and CXCL9 production after type I/II IFN and 
poly (I:C) stimulation compared to healthy controls. 
x AAD patients have normal humoral and cellular immunity towards CMV, but 
the levels of circulating CD8+ T cells in these patients are decreased. 
x Individual patients showed signs of primary or reactivating CMV infection, 
combined with low levels of CMV specific CD8+ T cells. One of these patients 
also had decreased CXCL10 production after IFN stimulations and an 
activated IFN signature, indicating that CMV could have played a role in 
disease development.  
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7. Future perspectives 
Although autoimmune Addison’s disease is a rare disease, the nation-wide Registry 
for organ specific autoimmune diseases (ROAS), including more than 700 patients, is 
an invaluable resource for research. Hopefully, with the help of ROAS, we will be 
able to answer even more of the unanswered questions regarding the pathogenesis of 
AAD.  
For future studies it would have been interesting to correlate more of the genetic data 
available to what we actually see when studying PBMC from patients for functional 
studies in the lab, for instance by investigating the effect of the PTPN22*1858T 
mutation in a larger sample size. The patients used in our experiments were not 
selected specifically, but were newly recruited patients or patients who had visited 
their local outpatient ward for their yearly check-up. Since we have DNA and serum 
from most of our patients at all times, we are able to establish which patients have the 
mutations in genes associated with AAD and also perform several analyses on sera, 
for instance check serostatus against different viruses. After having identified patients 
of interests, we could invite these patients to donate a blood sample for further 
evaluation using methodology now being implemented in our center.  
Next year the laboratory platform will be expanded to include the mass cytometry 
CyTOF system and the Fluidigm C1 system for single cell analysis, allowing the 
investigation of multiple parameters in one sample, and thus increasing the 
information we get from one donation of blood.  
In order to test our hypothesis, studying adrenal tissue or biopsies from diseased 
individuals will be invaluable. Specifically, this could allow us to investigate the 
presence of viral DNA and proteins, the in situ production of IFNs and CXCL10, and 
also the expression of CXCR3 on infiltrating lymphocytes. However, intact adrenal 
tissue from deceased patients with AAD is difficult to obtain, and so far only a few 
studies with limited material have been published. Addison’s disease is also known to 
affect both cats and dogs. A recent report show that adrenal tissue slides from 
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deceased dogs with confirmed or suspected Addison’s disease share similar traits as 
reported in humans, with lymphocytic infiltrations and atrophy of the adrenocortical 
cells [218]. Though, for future studies it might be easier to obtain tissue samples from 
dogs that have died while having the disease or as a result of the disease, to 
investigate whether there is any trace of a viral infection in the adrenals. Ideally we 
would have liked to investigate if a virus could induce adrenalitis or accelerate an 
autoimmune disease development in mice, but as of today there exists no relevant 
AAD mouse models. 
Finally, as our studies suggest that CXCL10 plays a role in the pathogenesis of AAD 
and is responsible for recruiting autoreactive T cells to the adrenal cortex, the 
prospect of clinical immunotherapy using monoclonal antibodies against CXCL10 
would be quite intriguing. Clinical trials using chemokine inhibitors have been 
initiated for various autoimmune diseases. In RA a phase II clinical trial, the fully 
human monoclonal antibody MDX-1100/BMS-936557 (anti-CXCL10) was given to 
patients already receiving methotrexate, and a significant clinical efficacy was 
demonstrated. In addition the antibody appeared to be well tolerated by the patients, 
with very few serious adverse effects [219]. The same antibody gave similar 
promising results in a phase II study of ulcerative colitis [220].  
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